All Life Advanced Immunology

All Life Advanced Immunology (ALAI) is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of next-generation cell therapies for cancer and autoimmune diseases. The company focuses on advancing chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies, with a particular emphasis on universal, off-the-shelf solutions and multi-target therapies. ALAI's pipeline includes candidates targeting CD19/CD20 for B-cell malignancies and BCMA/GPRC5D for multiple myeloma. Beyond oncology, the company is actively exploring the application of CAR-T therapies in severe autoimmune conditions such as systemic lupus erythematosus and myasthenia gravis. ALAI aims to improve the accessibility and efficacy of immunotherapy through innovative engineering and streamlined manufacturing processes.